Delpacibart Biosimilar – Anti-Transferrin receptor protein 1 mAb – Research Grade from ProteoGenix; catalogue PX-TA2058; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Delpacibart Biosimilar is a novel therapeutic antibody that targets the transferrin receptor protein 1 (TfR1). This biosimilar is a research grade version of the original Delpacibart antibody, which has shown promising results in pre-clinical studies. In this article, we will explore the structure, activity, and potential applications of Delpacibart Biosimilar in the field of antibody-based therapeutics.
Delpacibart Biosimilar is a monoclonal antibody (mAb) that specifically binds to TfR1, a transmembrane protein expressed on the surface of cells. The antibody is composed of two heavy chains and two light chains, linked together by disulfide bonds. The variable regions of the heavy and light chains determine the specificity of Delpacibart Biosimilar for TfR1.
Once bound to TfR1, Delpacibart Biosimilar inhibits the uptake of transferrin, a protein that transports iron into cells. This leads to a decrease in intracellular iron levels, which is essential for the growth and proliferation of cancer cells. Additionally, TfR1 is overexpressed in many types of cancer cells, making it an attractive therapeutic target for antibody-based treatments.
Delpacibart Biosimilar has the potential to be used in the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. By targeting TfR1, the antibody can inhibit the growth and proliferation of cancer cells, making it a promising therapy for these diseases.
Compared to traditional small molecule inhibitors, Delpacibart Biosimilar offers several advantages. As a monoclonal antibody, it has a high specificity for its target, minimizing off-target effects. It also has a longer half-life in the body, allowing for less frequent dosing. Additionally, Delpacibart Biosimilar can be easily modified to enhance its therapeutic properties, such as increasing its binding affinity or conjugating it with toxins for targeted delivery.
In pre-clinical studies, Delpacibart Biosimilar has shown promising results in inhibiting the growth of cancer cells in vitro and in vivo. In a study on breast cancer cells, the antibody was able to significantly reduce cell proliferation and induce cell death. In a mouse model of lung cancer, Delpacibart Biosimilar was shown to inhibit tumor growth and improve survival rates.
Based on the positive results from pre-clinical studies, Delpacibart Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer. These trials will assess the safety and efficacy of the antibody in human patients, with the goal of obtaining regulatory approval for its use in the clinic.
In summary, Delpacibart Biosimilar is a promising therapeutic antibody that targets TfR1, a protein overexpressed in many types of cancer cells. Its unique structure and mechanism of action make it a potential treatment option for various types of cancer. With ongoing clinical trials, Delpacibart Biosimilar has the potential to become a valuable addition to the arsenal of antibody-based therapeutics for cancer treatment.
ProteoGenix catalogue number PX-TA2058. For research use only.
Target: Delpacibart Biosimilar – Anti-Transferrin receptor protein 1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Delpacibart Biosimilar – Anti-Transferrin receptor protein 1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
